Highbridge Capital Management’s Blueprint Medicines BPMC Stock Holding History

Highbridge Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-189,822	Closed	-$24.3M	–	313
2025 Q2	$24.3M	Buy	+189,822	New	+$19.7M	0.99%	32
2017 Q1	–	Sell	-13,513	Closed	-$379K	–	1439
2016 Q4	$379K	Buy	+13,513	New	+$407K	0.01%	875

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Highbridge Capital Management's BPMC Position: Q3 2025 in Review

Highbridge Capital Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 189,822 shares — an estimated $24.3M sold.

Highbridge Capital Management first reported a position in BPMC in Q4 2016 and held it in 2 quarters. The position peaked at $24.3M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Highbridge Capital Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Highbridge Capital Management sold 189,822 Blueprint Medicines shares in Q3 2025, an estimated $24.3M.
Highbridge Capital Management first reported a position in Blueprint Medicines in Q4 2016 and held it in 2 quarters.
Highbridge Capital Management's Blueprint Medicines position peaked at $24.3M in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Highbridge Capital Management's 13F filing for Q3 2025, filed 10 Nov 2025.